

Glucagon-Like Peptide-1 Receptor Agonist and Gastrointestinal Adverse Effects: A Comprehensive Review

Julio Zúñiga Cisneros  · Michael Camilleri  · Madhusudan Grover 

Division of Gastroenterology and Hepatology, Mayo Clinic.
Rochester, Minnesota, USA.

Acta Gastroenterol Latinoam 2026;56(3):269-288

Received: 12/09/2026 / Accepted: 23/09/2026 / Published online: 30/09/2026 / <https://doi.org/10.52787/agl.v56i3.690>

Summary

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) has transformed the management of type 2 diabetes and obesity, with expanding indications now spanning cardiovascular, renal, and hepatic disease. As exposure broadens across increasingly diverse populations, gastrointestinal adverse events (GIAEs) have emerged as the dominant tolerability limitation and a leading drug-related reason for discontinuation of treatment. This review synthesizes the mechanisms, clinical spectrum, and management of GLP-1 RA-associated GIAEs. These effects arise from a dual peripheral-central mechanism: peripheral receptor activation slows gastric motility, whereas activation in the area postrema and nucleus tractus solitarius (NTS) drives nausea and emesis. This dual mechanism explains why symptom severity may correlate poorly with the measured degree of gastric-emptying delay

and why centrally acting antiemetics are most widely used to relieve nausea and emesis. Across clinical trials, nausea, emesis, diarrhea, constipation, and abdominal pain follow a consistent dose- and indication-dependent gradient, with the highest incidence observed with higher-dose obesity and MASH regimens and multi-agonist molecules. Most symptoms are mild, emerge during dose escalation, and attenuate over time, though a clinically important minority of patients experience persistent symptoms, and a subset develops gastroparesis. Management should rest on anticipation and screening of gastrointestinal symptoms at baseline, pretreatment counseling, gradual up-titration, and dietary measures before pharmacotherapy. Future priorities include standardized motility measurements and endpoints, predictive biomarkers, and evidence-based management algorithms.

Keywords. Glucagon-like peptide-1 receptors, drug-related side effects, nausea, gastroparesis, obesity, diabetes.

Efectos adversos gastrointestinales del agonista del receptor de GLP-1: revisión narrativa

Resumen

Los agonistas del receptor del péptido similar al glucagón tipo 1 (GLP-1 RA) han transformado el manejo de la diabetes mellitus tipo 2 y la obesidad, con indicaciones en expansión que abarcan enfermedades cardiovasculares, renales y he-

Correspondence: Madhusudan Grover
Email: grover.madhusudan@mayo.edu

páticas. A medida que su uso se extiende a poblaciones diversas, los eventos adversos gastrointestinales (GIAE) se han convertido en la principal limitación de tolerabilidad y una causa frecuente de suspensión del tratamiento. Esta revisión sintetiza los mecanismos, el espectro clínico y el manejo de los GIAE asociados con los GLP-1 RA. Estos efectos resultan de mecanismos periféricos y centrales: la activación periférica de los receptores enlentece la motilidad gástrica, mientras que la activación en el área postrema y el núcleo del tracto solitario podría contribuir a las náuseas y los vómitos. Esta dualidad explica la escasa correlación entre la intensidad de los síntomas y el retraso medido del vaciamiento gástrico, así como el uso frecuente de antieméticos de acción central. En ensayos clínicos, las náuseas, vómitos, diarrea, estreñimiento y dolor abdominal muestran un gradiente dependiente de la dosis y la indicación, con mayor frecuencia a dosis altas empleadas para obesidad y esteatohepatitis asociada a disfunción metabólica (MASH), así como con agonistas múltiples. La mayoría de los síntomas son leves, aparecen durante el escalamiento y disminuyen con el tiempo; sin embargo, una minoría presenta síntomas persistentes y un subgrupo desarrolla gastroparesia. El manejo debe ser anticipatorio e incluir evaluación basal, educación y medidas dietéticas antes del tratamiento farmacológico. Las prioridades futuras incluyen estandarizar las mediciones de motilidad gastrointestinal, identificar biomarcadores predictivos y desarrollar algoritmos de manejo basados en evidencia.

Palabras claves. Receptores del péptido similar al glucagón tipo 1, efectos adversos relacionados con los medicamentos, náuseas, gastroparesia, obesidad, diabetes.

Abbreviations

GLP-1 RA: Glucagon-like peptide-1 receptor agonist.

GIAEs: Gastrointestinal adverse events.

MASH: Metabolic dysfunction-associated steatohepatitis.

T2DM: Type 2 diabetes mellitus.

DGE: Delayed gastric emptying.

DPP-4: Dipeptidyl peptidase-4.

GIP: Glucose-dependent insulintropic polypeptide.

BMI: Body mass index.

MASLD: Metabolic dysfunction-associated steatotic liver disease.

CKD: Chronic kidney disease.

GI: Gastrointestinal.

CNS: Central nervous system.

cAMP: Cyclic adenosine monophosphate.

PKA: Protein kinase A.

GABA: Gamma-aminobutyric acid.

NTS: Nucleus tractus solitarius.

GET_{1/2}: Gastric half-emptying time.

CI: Confidence interval.

SMD: Standardized mean difference.

SC: Subcutaneous.

NNH: Number needed to harm.

RCT: Randomized controlled trial.

SGLT2: Sodium-glucose cotransporter-2.

IBS: Irritable bowel syndrome.

GERD: Gastroesophageal reflux disease.

IBD: Inflammatory bowel disease.

GFR: Estimated glomerular filtration rate.

GES: Gastric emptying scintigraphy.

1. Introduction and Prevalence of GLP-1 Use

1.1 Evolution and Therapeutic Indications of GLP-1 RA

GLP-1 RA represents a paradigm shift in managing T2DM and obesity in the last decade.^{1, 2} Their development traces to the 1960s discovery of the incretin effect, the observation that oral glucose elicits greater insulin secretion than intravenous glucose, implicating gut-derived hormones in glycemic regulation.^{3, 4} GLP-1 RA, secreted by intestinal L-cells in response to nutrient ingestion, modulates glucose homeostasis through insulin stimulation, glucagon suppression, DGE, and central satiety signaling.^{5–7}

The first GLP-1 RA, exenatide, a synthetic exendin-4 analogue, isolated from *Heloderma suspectum* saliva that shares 53% sequence homology with human GLP-1 and resists DPP-4 mediated degradation, received FDA approval in 2005. Subsequent agents expanded the class: liraglutide (2010), dulaglutide (2014), and semaglutide (2019).^{8, 9} GLP-1 RA is classified according to plasma half-life and duration of GLP-1 receptor activation as short-acting (exenatide twice-daily) or long-acting (lixisenatide once-daily, liraglutide once daily, and dulaglutide and semaglutide once-weekly). Tirzepatide, a dual GIP/GLP-1 RA, further broadened the therapeutic landscape following FDA approval in 2022–2023. Retatrutide, a triple GIP/GLP-1, is currently pending regulatory approval.¹⁰ Other dual agonists such as cagrilintide/semaglutide (which target the amylin receptors) are also in development.

Approved indications include glycemic control in T2DM, chronic weight management (BMI ≥ 30 kg/m², or ≥ 27 kg/m² with at least one weight-related comorbidity), MASLD/MASH, and cardiovascular risk reduction in T2DM patients with established atherosclerotic disease.^{9, 11–13} Emerging evidence continues to expand the therapeutic scope of this class. For example, the FLOW

trial has established a cardio-renal protective role in patients with CKD.¹⁴

1.2 Trends in the Use of GLP-1 RA

GLP-1 RA utilization has grown exponentially over the past decade, driven by expanding indications, robust efficacy data, and growing recognition of cardiometabolic benefits. Prescriptions of formulations approved only for T2DM agents (Ozempic, Rybelsus, Mounjaro, Victoza) grew at a mean annual rate of 38.5% between July 2017 and February 2024, from 0.3 to 3.5 million monthly prescriptions. In parallel, uptake among patients with comorbid T2DM and obesity climbed from 2.4% (2010) to 34.3% (2024), accelerating most steeply after the approvals of semaglutide and tirzepatide.^{15–17}

Real-world data from the NIH *All of Us* cohort reveal that nearly 40% of current GLP-1 RA users carry no T2DM diagnosis, reflecting substantial uptake for obesity management.¹⁸ This shift carries direct clinical relevance, as obesity-focused regimens typically employ higher doses and thus greater GI exposure than the doses required for glycemic indications.^{15, 19–20} As GLP-1 RA exposure expands across increasingly diverse patient groups, a thorough understanding of their gastrointestinal safety profile becomes essential for physicians.


2. Pathophysiological Mechanisms of Gastrointestinal Adverse Events

2.1 GLP-1 Receptor Distribution and Signaling

Understanding GLP-1 RA induced GIAEs requires familiarity with receptor distribution across the gut and CNS. The GLP-1 receptor is a class B G-protein-coupled receptor that, upon ligand binding, activates adenylyl cyclase, elevates intracellular cAMP, and engages downstream PKA and exchange protein directly activated by cAMP signaling pathways.^{21, 22}

GLP-1 receptors are expressed throughout the GI tract in gastric smooth muscle, enteric neurons, and vagal afferent terminals of the stomach; and in enteroendocrine cells, smooth muscle, and the myenteric plexus of the small intestine mediating effects on motility, secretion, accommodation, and nutrient absorption.^{5, 6, 23} Critically, GLP-1 receptors are also expressed in key CNS regions: the area postrema, NTS, hypothalamus, and brainstem.^{6, 22} The area postrema, lacking a complete blood-brain barrier, functions as a chemoreceptor trigger zone for emesis and carries high GLP-1 receptor density.^{24, 25} The NTS integrates vagal afferent input with central satiety and nausea pathways, forming a functional axis with peripheral gut signaling (See Figure 1).²²

Figure 1. Central and Peripheral Mechanisms Underlying the Therapeutic and Gastrointestinal Adverse Effects of GLP-1 Receptor Agonists



This dual peripheral-central receptor architecture explains both the therapeutic actions and GIAEs of GLP-1 RA. Emerging evidence suggests that peripheral GLP-1 receptor activation via vagal afferents and direct enteric nervous system signaling mediates DGE and altered motility, effects that are therapeutically desirable for suppressing postprandial glucose and inducing satiety.^{6, 22, 26, 27} In contrast, there is evidence from experimental animal studies that nausea and vomiting arise from central effects of GLP-1.²⁸

Centrally located GLP-1 receptors modulate gastric slow waves and cardiovascular function in ferrets consistent with the induction of nausea predominantly through central signaling, e.g. at the area postrema.^{28, 29} Preclinical studies demonstrate that area postrema-specific GLP-1 receptor ablation abolishes retching-like behavior without compromising metabolic benefits, suggesting a dissociation between emetic and metabolic pathways. While preserving therapeutic efficacy for glycemic control and satiety, GIP receptor co-agonism may attenuate emesis through GABAergic inhibitory neurons in the area postrema/NTS that locally silence the same emetic circuitry activated by GLP-1 receptor signaling.^{30, 31}

2.2 Effects on Gastric Emptying

DGE is one of the adverse effects most associated with GLP-1 RA, although the proportion of patients who objectively develop DGE varies across studies. However, this delay appears to attenuate over time, a phenomenon known as tolerance.^{8, 32–34}

Meier *et al.* demonstrated that intravenous GLP-1 infusion at pharmacological concentrations was associated with 74% gastric retention at 4 hours compared with 34% with placebo.³⁵ The magnitude of this effect is driven less by potency than by receptor-occupancy kinetics. Short-acting agents, such as twice-daily exenatide, have plasma half-lives of 2–3 hours and produce intermittent supraphysiologic receptor stimulation, preserving receptor sensitivity and causing pronounced, sustained delays in gastric emptying.³⁶ In a meta-analysis, GLP-1 RA significantly delays gastric emptying of solids, increasing GET_{1/2} by a mean of 74 minutes (95% CI, 46–101), with a large effect size (SMD 2.38; 95% CI, 1.05–3.71; $p < 0.001$). The delay was greater with short-acting agents, which prolonged GET_{1/2} by 116 minutes (SMD 3.86).³⁷ In contrast, long-acting agents, including liraglutide and dulaglutide, provide near-continuous receptor occupancy, leading to tolerance and attenuation of the gastric effect over time.^{36, 38}

This distinction has important clinical implications. Short-acting agents primarily reduce postprandial glucose excursions by slowing gastric emptying, whereas long-acting agents lower fasting glucose mainly through insulinotropic and glucagon-suppressive effects.^{36, 38, 39}

A longitudinal analysis from a clinical trial of patients with normal GE at baseline treated with liraglutide ($n = 67$) further illustrates this pattern: 57% developed significant DGE after treatment for 5 weeks, but tolerance led to normalization in approximately half of these patients by 16 weeks, leaving persistent delay in about 30%. Consistently, the median delay decreased from 70 minutes at 5 weeks to 30.5 minutes at 16 weeks, although it remained statistically significant.³⁴ This residual delay is clinically relevant: further analysis suggests that it correlates with weight loss, explaining approximately 20% of its variance, and that it may contribute to retained gastric contents and periprocedural aspiration risk.^{40, 41}

Although GLP-1 RA can delay gastric emptying, the severity of nausea does not correlate linearly with the degree of gastric delay.^{42–44} This dissociation is supported by the observation that long-acting agents may cause nausea despite tolerance of gastric effects.^{6, 22, 42} Overall, nausea appears to be driven primarily by central mechanisms, as discussed in Section 2.1. This is consistent with the greater clinical benefit of centrally acting antiemetics, such as ondansetron, compared with prokinetic agents.^{31, 45, 46}

Taken together, these observations support a multimodal approach that addresses both peripheral and central mechanisms, tailored to individual patient's symptom profile, consistent with the predominant clinical use of antiemetics.

2.3 Effects on Intestinal Motility and Transit

Beyond the stomach, GLP-1 RA significantly influences small intestinal and colonic motility, explaining the diverse GI symptoms encountered in clinical practice.

In the small intestine, a clinical trial in patients with T2DM demonstrated that exenatide reduces proximal pressure waves by approximately 30%, decreases intestinal flow velocity, and prolongs small bowel transit by 20–40 minutes.²³ These effects attenuate nutrient absorption and enhance incretin signaling contributing to therapeutic efficacy but also likely predispose to bloating, abdominal discomfort, and altered bowel habits.^{6, 23}

Effects of GLP-1 RA on small intestinal motility can also be inferred from a 4-week treatment cross-over study with daily SC administration of liraglutide (dose escalated from 0.6 mg to 1.8 mg/day), which reduced chronic high bowel frequency in eight patients with colectomy and ileal pouch anal anastomosis.⁴⁷

Colonic responses are more heterogeneous and likely explain the paradoxical occurrence of diarrhea and constipation across patients. Some evidence supports delayed colonic transit favoring constipation, while other data suggest accelerated transit or altered secretion driving diarrhea.^{32, 48, 49} A retrospective case series using the wireless motility capsule documented prolonged whole-gut transit time in more than 40% of patients treated with GLP-1 RA.⁵⁰ A preliminary report of a propensity score-weighted retrospective cohort study of adult patients with T2DM and/or obesity who underwent clinically-indicated whole-gut transit assessment over 48 hours at a tertiary referral practice found that GLP-1 receptor agonist is associated with delayed colonic transit in almost 30% of individuals, compared with less than 20% in controls.⁵¹

The mechanisms likely involve direct effects on colonic smooth muscle, enteric nervous system modulation, and altered nutrient delivery from changes in upper gastrointestinal transit. This heterogeneity may reflect differences in GLP-1 receptor signaling pathways, regional colonic effects, and patient-specific factors, all of which remain under investigation.^{22, 32, 33, 48, 52}

GLP-1 RA may additionally influence intestinal secretion and mucosal permeability through enterocyte-level effects, though these mechanisms remain incompletely characterized.^{52, 53}

2.4 Pharmacokinetic and Pharmacodynamic Factors

The gastrointestinal tolerability of GLP-1 RA is influenced by four key pharmacological factors: dose-response relationships, formulation class, tolerance, and drug interactions.^{8, 54}

Higher doses of GLP-1 RA are associated with an increased risk of GIAEs.^{54, 56} These events, most commonly nausea, vomiting, diarrhea, and constipation, follow a consistent dose-response pattern and occur most frequently during dose escalation.⁵⁶ Higher event rates have been reported with maximal or higher doses of dulaglutide, semaglutide, and tirzepatide in clinical trials (See Table 1).

Although formulation class and pharmacokinetic profile influence the pattern of GIAEs, they do not reliably predict overall tolerability.^{10, 56, 57} In general, long-acting

agents provide steadier drug exposure, and are often considered better tolerated.^{4, 7, 32, 58} However, clinical trial data do not uniformly support this assumption, as several long-acting agents, particularly higher-dose semaglutide and tirzepatide, are consistently associated with GIAEs (See Table 1). In contrast, the oral versus injectable route appears less important once dose and systemic exposure are considered, with agent-specific properties driving much of the variability.⁵⁴

Tolerance and longer exposure may reduce gastrointestinal symptoms during GLP-1 RA therapy.^{6, 23, 33, 59} Gastric emptying delay and related symptoms often attenuate after initiation, as discussed in Section 2.2. This adaptation appears stronger for peripheral motility effects than for centrally mediated nausea, which may persist in susceptible patients.^{24, 25, 32}

Finally, data on drug–drug and comorbidity interactions affecting GLP-1 RA gastrointestinal tolerability remain limited. Some evidence suggests additive symptom burden with metformin and higher risk with motility-slowing agents or baseline gastroparesis; however, recommendations largely rely on indirect analyses, case series, and expert guidance.^{54–56, 60–62}

3. Clinical Manifestations of GIAEs

GI-related discontinuation is a clinically important marker of tolerability. In randomized trials, discontinuation attributable to GIAEs ranges from under 2% to approximately 19% with high-dose GLP-1 RA varying by agent, dose, indication, and trial design.^{8, 57, 63} Nausea and vomiting account for most withdrawals, followed by diarrhea, abdominal pain, and constipation (See Table 1).

Discontinuation usually occurs during dose escalation, when symptoms peak; for example, in the STEP program trials, the cumulative incidence of first GIAEs plateaued after week 20, and most discontinuations occurred within the escalation period. Risk is higher with rapid escalation, baseline GI symptoms, metformin use, pre-existing GI disease, female sex, and obesity.^{10, 15, 45, 61, 64} Notably, elevated GI symptom rates did not uniformly translate into treatment discontinuation: in ESSENCE, discontinuation due to adverse events was numerically lower with semaglutide than placebo despite substantially higher GI event rates, and in the randomized phase of STEP-4 discontinuation was nearly identical between treatment arms, suggesting that with gradual titration, established tolerance, and adequate counseling, GIAEs are largely manageable.^{13, 65}

Table 1. Reported Gastrointestinal Adverse Events in GLP-1 Receptor Agonist Clinical Trials, Stratified by Treatment Indication

Trial (Name)	Intervention	Main Outcome	GIAEs†	GIRD‡	Total % reported GIAEs	NNH (Leading to discontinuation for all causes)§
Diabetes Trials						
SUSTAIN-6 ⁷³	Semaglutide 0.5-1.0 mg SC	MACE: HR 0.74 ($p = 0.02$); HbA1c ↓ 1.0-1.1%	Nausea: 17.3% vs 6% Vomiting: 10.5% vs 3.5% Diarrhea: 17.9% vs 9% Constipation: 8% vs 4.5% Abdominal pain: 7% vs 5%	5.1% vs 0.9%	42% vs 22%	15/17
SUSTAIN 1 to 5 ¹⁰⁵	Semaglutide SC 0.5-1.0 mg SC	HbA1c ↓ -1.2% to -1.8% vs comparators; weight ↓ 3-6 kg	Nausea: 15-19% vs 6% Diarrhea: 10-13% vs 6% Vomiting: 7-8% vs 3% Constipation: 6% vs 3-4%	5.1% vs 0.9%	39-42% vs 22-25%	18-21
PIONEER1-8 ^{60, 67, 83-84, 86-87}	Oral semaglutide (3/7/14 mg) vs placebo	HbA1c ↓ -0.6% to -1.5% vs comparators (placebo, empagliflozin, sitagliptin, liraglutide)	Nausea: 15.4-19.1% vs 6.3% Diarrhea: 10.1-12.6% vs 5.7% Vomiting: 6.6-7.5% vs 2.8-3.3% Constipation: 5.8-6.5% vs 2.7-3.7%	8.7 vs 4.2%	39.1% vs 24.8%	22
SOUL ¹⁰⁵	Oral Semaglutide 14 mg vs placebo	MACE: HR 0.86 (95% CI 0.77-0.96, $p = 0.006$). First oral GLP-1 CV benefit	Nausea: 15% vs 5% Vomiting: 8% vs 3% Diarrhea: 11% vs 6% Constipation: 8% vs 4%	6.4% vs 2.0%	45% vs 20%	26
SURPASS-1 ⁸²	Tirzepatide 5/10/ 15 mg vs placebo (T2DM)	HbA1c ↓ -2.09% (15 mg) vs +0.04% placebo; $p < 0.001$	Nausea: 12-18% vs 6% Vomiting: 4-8% vs 2% Diarrhea: 12-22% vs 8% Constipation: 6-11% vs 4% Abdominal pain: 5-7% vs 3%	2/5/7% vs 1%	36-50% vs 22%	NC/50/25
SURPASS-2 ⁹¹	Tirzepatide 5/10/15 mg vs semaglutide 1 mg	HbA1c ↓ -2.01% with 5 mg; -2.30% with 15 mg vs -1.86% semaglutide 1 mg; superior weight loss	Nausea: 17-22% vs 18% Vomiting: 7-12% vs 11% Diarrhea: 14-20% vs 16% Constipation: 7-11% vs 9%	5.1/ 7.7/ 7.9 vs 3.8%	40-55% vs 45%	77/26/24
SURPASS-3 ¹²²	Tirzepatide 5/10/15 mg vs insulin degludec	HbA1c ↓ -2.37% with 15 mg) vs -1.34% with insulin degludec; weight ↓ -13.9 kg vs +3.0 kg	Nausea: 12/18/24% vs 2% Vomiting: 6/8/10% vs 1% Diarrhea: 15/15/17% vs 4% Constipation: 8-13% vs 3% Abdominal pain: 5-8% vs 3%	3-7% vs 1%	42-58% vs 18%	20
SURPASS-4 ⁷²	Tirzepatide 5/10/15 mg vs insulin glargine	HbA1c ↓ -2.24% with 5 mg; -2.58% with 15 mg vs -1.44% insulin glargine; CV safety established	Nausea: 12/16/23% vs 2% Vomiting: 5/8/9% vs 2% Diarrhea: 13/20/22% vs 4% Constipation: 5/4/4% vs 1% Abdominal pain: 6-8% vs 3%	3-11% vs 1%	33-53% vs 19%	17/25/17
SURPASS-5 ⁷⁰	Tirzepatide 5/10/15 mg vs placebo (on insulin)	HbA1c ↓ -2.11% is 5 mg; 15 mg was -2.34% vs -0.86% placebo (on insulin); weight ↓ -9.5 kg	Nausea: 13/15/18% vs 2.5% Vomiting: 7/9/13% vs 2.5% Diarrhea: 12/17/21% vs 10% Constipation: 9-13% vs 4% Abdominal pain: 6-8 vs 3	5/6/7% vs 1%	46-58% vs 22%	29/17/12
SURPASS-CVOT ⁸⁸	Tirzepatide up to 15 mg vs dulaglutide 1.5 mg	MACE: HR 0.92 (95% CI 0.83-1.01); non-inferiority vs dulaglutide	Nausea: 25.1% vs 22.4% Vomiting: 9% vs 6% Diarrhea: 24.8% vs 19% Constipation: 10% vs 7% Abdominal pain: 6% vs 5% Pancreatitis 0.6% vs 0.6%	13.3% vs 10.2%	42.5% vs 36%	15

Continues A, B, C

Continuation A. Table 1.

Trial (Name)	Intervention	Main Outcome	GIAEs†	GIRD‡	Total % reported GIAEs	NNH (Leading to discontinuation for all causes)§
REWIND ⁹⁴	Dulaglutide 1.5 mg weekly vs placebo	MACE: 12.0% (dulaglutide) vs 13.4% (placebo) HR 0.88 ($p = 0.026$); broader primary prevention	Nausea: 12.4% vs 6.4% Vomiting: 6.6% vs 3.3% Diarrhea: 12.6% vs 7.7% Constipation: 5.9% vs 4.3% Abdominal pain: 6.4% vs 4.8%	1-3% vs 0	47.4 vs 34.1%	35
EXSCEL ¹²³	Exenatide ER 2 mg weekly vs placebo	11.4% (exenatide) vs 12.2% (placebo) HR 0.91 (95% CI 0.83-1.00). Exenatide met noninferiority ($p < 0.001$) but did not achieve superiority ($p = 0.06$)	Nausea: 10.2% vs 5.5% Vomiting: 6.8% vs 3.2% Diarrhea: 9.3% vs 6% Constipation: 4.5% vs 3.5% Abdominal pain: 5.4 %vs 4%	Not reported	Not reported	NC
ELIXA ¹²⁴	T2DM recent ACS. Lixisenatide 10-20 mcg daily vs placebo	MACE: HR 1.02 (95% CI 0.89-1.17; $p < 0.001$ for noninferiority, $p = 0.81$ for superiority)	Nausea: 24% vs 10% Vomiting: 10.5% vs 4% Diarrhea: 8% vs 5.5% Constipation: 3.5% vs 2.5% Abdominal pain: 5.5% vs 4.5%	4.9% vs 1.2%	30-36% vs 6-14%	24
HARMONY (CVOT) ⁵⁸	Albiglutide 30-50 mg weekly vs placebo	MACE: 7% (albiglutide) vs 9% (placebo) – HR 0.78 (95% CI 0.68-0.90; $p = 0.0006$ for superiority)	Nausea: 23.7% vs 12% Vomiting: 9.5% vs 4.2% Diarrhea: 13.8% vs 8.8% Constipation: 6.5% vs 4.5% Abdominal pain: 6.5% vs 4.5%	1.7% vs 1.5%	41.9% vs 35.5%	NC
TRANSCEND T2D-1 (Phase 3, 40 wk, $n = 537$) ⁶⁸	Retatrutide 4/9/12 mg SC weekly vs placebo (2 mg start, 4-weekly escalation)	HbA1c ↓ –1.69% / –1.86% / –1.94% (4/9/12 mg) vs –0.81% placebo; ETD –0.88% / –1.04% / –1.12%, all $p < 0.0001$. Weight ↓ –11.5% / –13.9% / –15.3% vs –2.6%	Nausea: 16.4/19.5 / 26.5% vs 3.7 Vomiting: 15.7/15.0 / 17.6% vs 2.2% Diarrhea: 18.7/26.3 / 22.8% vs 4.5%	2.2/ 4.5/ 5.1% vs 0	68-80% vs 28%	46/23/20
Obesity Trials						
STEP-1 ⁷⁴	Semaglutide 2.4 mg vs placebo	Weight ↓ –14.9% vs –2.4% placebo; $p < 0.001$	Nausea: 44% vs 17.4% Diarrhea: 30% vs 15.9% Vomiting: 24.8% vs 6.6% Constipation: 24% vs 11%	4.5% vs 0.8%	73% vs 36%	27
STEP-2 (T2DM) ⁷¹	Semaglutide 2.4 mg vs 1.0 mg vs placebo (all groups lifestyle intervention)	Weight ↓ –9.6% vs –7% vs –3.4% placebo; $p < 0.001$	Nausea: 32.1% vs 14.1% Vomiting: 15.1% vs 5.4% Diarrhea: 19.5% vs 10.3% Constipation: 18.4% vs 9.8% Abdominal pain: 10.3% vs 6.7%	6.2%/ 5% vs 3.5%	63.5/ 57.5% vs 33%	37
STEP-3 ⁸⁰	Semaglutide 2.4 mg weekly vs placebo both groups intensive behavioral therapy	Weight ↓ –16.0% vs –5.7%; superior to lifestyle alone	Nausea: 58.2% vs 22.1% Vomiting: 27.3% vs 10.8% Diarrhea: 36% vs 22.1% Constipation: 22% vs 11.3%	3.4% vs 0%	82.8% vs 63.2%	33
STEP-4 (maintenance) ⁶⁵	Semaglutide 2.4 mg subcutaneously once weekly (16-week dose escalation, followed by maintenance to week 20); responders randomized 2:1 to continue semaglutide 2.4 mg or switch to placebo	Continued semaglutide –7.9% vs +6.9% (withdrawal); sustained loss with treatment	Nausea: 14.0% vs 4.9% Diarrhea: 14.4% vs 7.1% Constipation: 11.6% vs 6.3%	2.4% vs 2.2%	41.9% vs 26.1%	No difference (500)

Continuation B. Table 1.

Trial (Name)	Intervention	Main Outcome	GIAEs†	GIRD‡	Total % reported GIAEs	NNH (Leading to discontinuation for all causes)§
STEP-5 ¹²⁵	Semaglutide 2.4 mg vs placebo	Weight ↓ −15.2% vs −2.6% at 104 wks; sustained benefit	Nausea: 43% vs 16% Vomiting: 25% vs 7% Diarrhea: 30% vs 16% Constipation: 24% vs 11% Abdominal pain: 12% vs 8%	5.9% vs 4.6%	72% vs 35%	77
SELECT ¹⁰⁶	Semaglutide 2.4 mg vs placebo (no diabetes)	MACE HR 0.80 ($p < 0.001$); 20% CV risk ↓ in obese, no T2DM	Nausea: 44% vs 16% Vomiting: 25% vs 7% Diarrhea: 30% vs 16% Constipation: 24% vs 11% Abdominal pain: 12% vs 8%	10% vs 2%	74% vs 36%	13
SURMOUNT-1 ⁷⁹	Tirzepatide 5/10/15 mg vs placebo, randomization 1:1:1:1	Weight 72 weeks↓: Tirzepatide 5 mg: −15.0% Tirzepatide 10 mg: −19.5% Tirzepatide 15 mg: −20.9% Placebo: −3.1% ($p < 0.001$ for all)	Nausea: 24/33/31% vs 9.5% Vomiting: 8.3/10.7/12.2% vs 1.7% Diarrhea: 18.7/21.2/23% vs 7.3% Constipation: 16.8/17/12% vs 5.8% Abdominal pain: 9-12% vs 5% Dyspepsia: 8.9/9.7/11.3% vs 4.2%	1-10.5%	27.8 -72.8 vs 12.2	28
SURMOUNT-2 (T2D) ⁹⁰	Tirzepatide 10/15 mg vs placebo, randomization 1:1:1	Weight ↓ at 72 weeks: Tirzepatide 10 mg: −12.8% Tirzepatide 15 mg: −14.7% Placebo: −3.2% ($p < 0.0001$ for both)	Nausea: 20/22% vs 6% Vomiting: 11/13% vs 3% Diarrhea: 20/22% vs 9% Constipation: 8/9% vs 4%	4/7% vs 4%	40-55% vs 24%	33
SURMOUNT-3 ⁷⁷	Tirzepatide (maximum tolerated dose 10 or 15 mg) once weekly for 72 weeks following a 12-week intensive lifestyle intervention; randomized 1:1 to tirzepatide or placebo	Weight ↓ −18.4% (tirzepatide after lifestyle run-in) vs +2.5% placebo	Nausea: 39.7% vs 14% Vomiting: 13% vs 3% Diarrhea: 31% vs 9.2% Constipation: 23% vs 6.8%	10.5% vs 2%	55% vs 22%	12
SURMOUNT-4 ⁷⁸	Tirzepatide (maximum tolerated dose 10 or 15 mg) once weekly. Participants who tolerated treatment were then randomized 1:1 to continue tirzepatide or switch to placebo	Weight regains -5.5% vs +14.0% after withdrawal; continued loss with treatment	Nausea: 8.1% vs 2.7% Vomiting: 5.7% vs 1.2% Diarrhea: 10.7% vs 4.8% Constipation: 14% vs 5% Abdominal pain: 8 vs 4%	7.0 % initially then after randomization 1.8% vs 0.9%	50% vs 22%	111 (randomization period)
SCALE (Obesity) ⁸⁵	Liraglutide 3.0 mg daily vs placebo	Weight ↓ −8.4 kg vs −2.8 kg placebo at 56 wks; $p < 0.001$	Nausea: 41% vs 17% Vomiting: 15.7% vs 4.3% Diarrhea: 25% vs 10% Constipation: 19.4% vs 8.5% Abdominal pain: 11.5% vs 6.5%	6.4% vs 0.7%	68% vs 28%	18
Retatrutide Ph2 Obesity ⁷⁵	Retatrutide 4–12 mg vs placebo	Weight ↓ Placebo: −2.1% Retatrutide 1 mg: −8.7% Retatrutide 4 mg (combined): −17.1% Retatrutide 8 mg (combined): −22.8% Retatrutide 12 mg: −24.2% ($p < 0.001$ for all vs placebo) at 48 wks	Nausea: 14-45% vs 11% Vomiting: 3-26% vs 1% Diarrhea: 9-20% vs 11% Constipation: 7-16% vs 3% Abdominal pain: 12-18% vs 4%	7-8% vs 0%	70-85% vs 28%	6

Continuation C. Table 1.

Trial (Name)	Intervention	Main Outcome	GIAEs†	GIRD‡	Total % reported GIAEs	NNH (Leading to discontinuation for all causes)§
CKD Trials						
FLOW (CKD + T2DM) Semaglutide ¹⁴	Patients with T2DM and CKD were randomized 1:1 to semaglutide 1.0 mg subcutaneously once weekly (n = 1,767) or placebo (n = 1,766)	Kidney composite HR 0.76 ($p < 0.001$); eGFR decline ↓; CV death ↓ 29%	Not reported GIAEs individually.	4.5% vs 1.1%	42% vs 20%	77
NASH/MASH Trials						
ESSENCE (MASH Ph3) ¹³	Patients with biopsy-confirmed MASH and fibrosis stage F2/F3 were randomized 2:1 to semaglutide 2.4 mg subcutaneously once weekly or placebo	MASH resolution + no fibrosis worsening: 62.9% vs 34.3% ($p < 0.001$) Fibrosis improvement ≥ 1 stage without worsening of MASH: 36.8% vs 22.4%	Nausea: 36.3% vs 13.2% Diarrhea: 26.9% vs 12.2%, Constipation: 22.3% vs 8.4%, Vomiting: 18.6% vs 5.6% Abdominal pain: 13% vs 8%	2.6% vs 3%	74% vs 37%	15
SYNERGY-NASH (Ph3) ⁷⁶	Adults with biopsy-confirmed MASH and stage F2/F3 fibrosis were randomized to tirzepatide 5 mg, 10 mg, or 15 mg subcutaneously once weekly, or placebo, for 52 weeks	MASH resolution Placebo: 10% Tirzepatide 5 mg: 44% (difference vs placebo: 34 pp; $p < 0.001$) Tirzepatide 10 mg: 56% (difference: 46 pp; $p < 0.001$) Tirzepatide 15 mg: 62% (difference: 53 pp; $p < 0.001$)	Nausea: 35/34/44% vs 12% Vomiting: 6/6/15% vs 2% Diarrhea: 32/36/27% vs 23% Constipation: 23/19/15% vs 6% Abdominal pain: 6/6/12% vs 8% Abdominal distention: 6/6/12% vs 8%	4/0/4% vs 2%	91/94/92% vs 83%	25 (15 mg dose), rest of dose not calculable.
LEAN (NASH) ⁹²	Overweight adults with biopsy-confirmed NASH were randomized 1:1 to liraglutide 1.8 mg subcutaneously once daily or placebo for 48 weeks	NASH resolution 39% vs 9% ($p = 0.019$); pilot trial (RR:4.3, $p = 0.019$)	Nausea: 46% vs 38% Vomiting: 19% vs 12% Diarrhea: 38% vs 19% Constipation: 27% vs 0 Dyspepsia: 15% vs 4% Bloating: 15% vs 0	19% vs 19%	81% vs 65%	6

GIAEs rates are presented as active treatment versus comparator. When multiple dose groups were reported, ranges or dose-specific values are shown when were available. NNH values were not calculated when insufficient data were available.

Abbreviations: ACS (acute coronary syndrome), CKD (chronic kidney disease), CV (cardiovascular), CVOT (cardiovascular outcomes trial), eGFR (estimated glomerular filtration rate), GIRD (gastrointestinal-related drug discontinuation), GIAEs (gastrointestinal adverse events), HbA1c (glycated hemoglobin), HR (hazard ratio), MACE (major adverse cardiovascular events), MASH (metabolic dysfunction-associated steatohepatitis), NASH (nonalcoholic steatohepatitis), NNH (number needed to harm), NR (not reported), SC (subcutaneous), T2DM (type 2 diabetes), NC (not calculable).

† GIAEs represents the proportion of participants experiencing at least one gastrointestinal adverse event (e.g., nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, or bloating) as reported in each trial.

‡ GIRD represents the proportion of participants who discontinued study treatment because of gastrointestinal adverse events.

§ Overall NNH leading to discontinuation was calculated using the absolute risk increase for any adverse event leading to treatment discontinuation (all-cause adverse event discontinuation), comparing the active treatment with the control group. NNH is based on all-cause AE discontinuation because it is reported consistently across trials and is the most clinically actionable endpoint; across programs, gastrointestinal events were the predominant driver of treatment discontinuation.

3.1 Nausea

Nausea is the most frequently reported GIAEs across GLP-1 RA-based therapy trials, ranging from approximately 10% to 58%.^{66–72} The estimated nausea-specific

NNH versus placebo ranged from approximately 3 in high-dose obesity trials to over 20 with diabetes-dose regimens, meaning that one additional case of nausea occurred for every 3 to 20 patients treated. In active-com-

parator trials such as SURPASS-2, the excess nausea risk with tirzepatide versus semaglutide 1 mg was minimal, and a meaningful NNH could not be derived. Semaglutide demonstrated a clear dose- and indication-dependent increase, with nausea increasing from approximately 15-19% in diabetes trials, 32-58% in obesity trials and approximately 36% in MASH (ESSENCE).^{13, 73 - 74} Lower NNH values were observed with retatrutide (a triple GIP/GLP-1/glucagon receptor agonist) and higher-dose obesity or MASH regimens, indicating a stronger nausea risk for this group of patients.^{13, 72, 75 - 79}

3.2 Vomiting

Vomiting was reported less frequently than nausea but followed a similar dose- and indication-dependent pattern. Across trials, vomiting ranged from approximately 4% to 27%, with an estimated vomiting-specific NNH versus placebo of approximately 5 to over 50.^{23, 64, 65, 74, 77, 80 - 86} For semaglutide, vomiting rates were lower in diabetes and CKD trials, generally ranging from 5% to 10.5%, but increased to 15% to 25% in higher-dose obesity and MASH trials.^{13, 14, 65, 81, 83, 84, 86 - 89} For tirzepatide, vomiting ranged from 4% to 12% in diabetes trials and increased to approximately 11% to 20% in obesity trials and MASH trials.^{76, 77, 79, 82, 90, 91} A distinctive vomiting signal was observed with retatrutide: in TRANSCEND-T2D-1, vomiting reached 15.7-17.6% of patients versus 2.2% with placebo at diabetes doses rates, comparable to those observed with semaglutide only at obesity doses. These findings yielded among the lowest vomiting-specific NNH values (~7-8) in the diabetes trials.^{68, 75}

3.3 Diarrhea

Diarrhea was commonly reported across GLP-1 RA-based therapy trials, with rates ranging from approximately 7% to 38%. For semaglutide, diarrhea rates were lower in diabetes and CKD trials, generally ranging from 10% to 17.9%, but increased to approximately 19.5% to 30% in higher-dose obesity and MASH trials.^{13, 14, 65, 81, 83 - 84, 86 - 89}

For tirzepatide, diarrhea ranged from 12% to 22% in diabetes trials and approximately 14% to 23% in obesity trials and MASH trials.^{76, 77, 79, 82, 90 - 91} The highest diarrhea rates were observed with retatrutide in TRANSCEND-T2D-1 (18.7-26.3% vs 4.5%) and with li-raglutide in LEAN (38% vs 19%), although the latter derives from a pilot trial of 52 patients and should therefore be interpreted with caution. Notably, in TRANSCEND-T2D-1 diarrhea exceeded nausea at the 9 mg dose, a pattern not typical of isolated GLP-1 receptor agonist and possibly reflecting glucagon-receptor agonist

mediated effects on intestinal secretion and transit.^{68, 75, 92}

Real-world studies report higher diarrhea rates with GLP-1 RA than those reported in clinical trials, likely reflecting broader populations and longer follow-up.¹⁸ Diarrhea may occur early after the treatment or persist, reflecting variable effects on intestinal motility and secretion.⁹³ Persistent or severe diarrhea warrants evaluation for alternative causes, including concomitant pharmacotherapy use, GI infections, IBD, celiac disease, microscopic colitis, bile acid malabsorption, and pancreatic insufficiency.

3.4 Constipation

Constipation was reported across GLP-1 RA-based therapy trials, with rates ranging from approximately 3.5% to 24%, and up to 27% in the small LEAN pilot (versus 0% with placebo). The estimated constipation-specific NNH ranged from ~4 to ~90.^{76, 79, 92, 94} Constipation associated with GLP-1 RA may occur either early after treatment initiation or after months of therapy and in severe cases can lead to fecal impaction or bowel obstruction. Patients with pre-existing constipation, slow-transit constipation, or pelvic floor dysfunction are at increased risk and require close monitoring.^{32, 95}

For semaglutide, constipation was relatively infrequent in diabetes patients and CKD trials, including SUSTAIN-6 and SOUL, ranging from 6% to 8%, but increased to approximately 16% to 24.2% in higher-dose obesity and MASH trials.^{13, 65, 81, 83 - 84, 86 - 89}

For tirzepatide, constipation ranged from 6% to 13% in SURPASS diabetes trials and approximately 12% to 22% in SURMOUNT obesity trials and SYNERGY-NASH.^{76 - 77, 79, 82, 90 - 91} In the phase 2 obesity trial, retatrutide was associated with constipation in 7-16% of participants versus 3% with placebo; constipation was not reported among the most frequent adverse events in the phase 3 TRANSCEND-T2D-1 topline data, and dose-specific rates await full publication.^{68, 75}

3.5 Abdominal Pain and Discomfort

Abdominal pain was less frequent and less consistently reported than other GIAEs. Across trials that included this outcome, abdominal pain ranged from approximately 5% to 18%.^{13, 38, 49, 60, 64, 75, 77, 80, 87, 96} For semaglutide, rates were lower in diabetes and CKD trials, ranging from 5.5% to 7%, but increased to approximately 10.3% to 13% in higher-dose obesity and MASH trials.^{13 - 14, 65, 81, 83 - 84, 86 - 89} For tirzepatide, abdominal pain ranged from 5% to 8% in diabetes trials and approximately 6% to 12% in obesity trials and MASH. The strongest rates were observed with retatrutide in the phase 2 obesity

trial, where abdominal pain reached 12-18% versus 4% with placebo; notably, abdominal pain was not reported in the TRANSCEND-T2D-1 topline data.^{68, 75}

3.6 Gastroparesis and Severe Gastric Dysmotility

Although DGE is a pharmacological class effect of GLP-1 RA, clinically significant gastroparesis occurs in only a subset of users. Reported incidence varies, with real-world estimates around 5.1%.¹⁸ Risk is higher with baseline dysmotility, diabetic autonomic neuropathy, rapid escalation, higher doses, female sex, and motility-altering drugs. Diagnosis requires compatible symptoms, objectively documented DGE of solids, and exclusion of mechanical obstruction. The extent to which these changes are reversible after drug discontinuation remains incompletely defined.^{8, 19, 39, 42, 57, 97–98}

3.7 Biliary Adverse Events

Biliary adverse events occur in approximately 1-3% of patients treated with GLP-1 RA, with randomized evidence demonstrating a modest class-wide increase driven predominantly by cholelithiasis.⁵⁵ A meta-analysis of 76 randomized controlled trials (RCT; > 100,000 participants) reported increased risks of composite gallbladder/biliary disease (RR 1.37), cholelithiasis (RR 1.27), cholecystitis (RR 1.36), biliary disease (RR 1.55), and cholecystectomy (RR 1.70), with greater risk at higher doses, treatment durations > 26 weeks, and weight-loss indications.⁹⁹ Liraglutide demonstrated the highest drug-specific risk (RR 1.79) for cholecystitis or cholelithiasis, followed by dulaglutide (RR 1.35), whereas high-dose SC semaglutide showed increased risk (RR 1.58 for ≥ 1.0 mg); risk with exenatide was borderline, while oral semaglutide, lixisenatide, and albiglutide were not significantly associated.⁹⁹ More recent placebo-controlled data confirmed increased cholelithiasis (RR 1.46) but not cholecystitis or cholangitis.¹⁰⁰ Observational data similarly suggest a modest increase in comparison to SGLT2 inhibitors (HR 1.15), although absolute excess risk remains low.¹⁰¹ Mechanistically, GLP-1 RA reduces gallbladder motility and emptying, potentially through suppression of cholecystokinin, while rapid weight loss promotes biliary cholesterol supersaturation.^{55, 97} Risk appears cumulative, generally emerging after approximately 6 months and diverging from comparator therapies after longer follow-up. In contrast, pancreatitis risk remains reassuring. Placebo-controlled RCT and large cohorts demonstrate no clinically meaningful increase, although isolated observational studies report small, predominantly early signals.^{99–100, 102} No GLP-1 RA has a consistent pancreatitis-specific risk in high-quality evi-

dence; pharmacovigilance signals, particularly for liraglutide, remain hypothesis-generating and do not prove definite association. Overall, biliary complications represent an uncommon but clinically relevant class effect, whereas acute pancreatitis is not supported as a major GLP-1 RA toxicity. Risk assessment should consider dose, duration, indication, and magnitude of weight loss.

4. Impact of GIAEs in Specific Patient Populations

4.1 Patients with T2DM vs Patients with Obesity

GLP-1 RA gastrointestinal tolerability appears driven more by dose, agent, and patient factors than by diabetes versus obesity status alone.^{17, 56, 60} Patients with T2DM may have baseline delayed or rapid gastric emptying from autonomic neuropathy, whereas patients with obesity but without diabetes often have preserved gastric reserve.^{5, 103–104} Notably, at identical doses, patients with T2DM consistently report lower GIAEs than those without diabetes. With semaglutide 2.4 mg, nausea occurred in 32.1% of patients with T2DM (STEP-2) versus 44% of those without diabetes (STEP-1); similarly, with tirzepatide, a similar pattern is seen between SURMOUNT-2 (nausea 20-22%) and SURMOUNT-1 (24–33%) (Table 1). Proposed explanations include diabetes-related autonomic dysfunction blunting visceral afferent signaling, prior incretin or metformin exposure, and differences in baseline gastric physiology.^{8, 33, 55–57} The higher symptom burden in patients treated for obesity underscores the importance of gradual titration, counseling, and education to reduce premature discontinuation during therapy.

4.2 Pre-existing GI Disorders

Patients with pre-existing GI disorders are at higher risk of GLP-1 RA-related adverse events and require individualized selection, counseling, and monitoring. Symptomatic gastroparesis or diabetic autonomic neuropathy may predispose patients to severe nausea, vomiting, early satiety, and nutritional compromise, making these baseline conditions a relative contraindication in selected cases; when treatment is pursued despite these conditions, the slowest available titration schedule and early reassessment are advisable.^{8, 54–55, 57, 64} IBS symptoms may worsen according to subtype, although improvement of the bowel dysfunction symptoms is possible. GERD effects are variable, reflecting competing influences of DGE and weight loss.^{5, 33, 108} Overall, severe gastroparesis, bowel obstruction, severe IBD, and pancreatitis warrant careful risk-benefit assessment before commencing GLP-1 RA treatment.^{54–55, 57, 97} Importantly, the trials summarized in

Table 1 systematically excluded patients with significant pre-existing GI disease, gastroparesis, or prior bariatric surgery. The adverse event rates summarized in Table 1 therefore describe a GI-healthy population and likely underestimate the symptom burden in the patients discussed in this section, for whom no randomized safety data exist.

4.3 Age-Related Differences

Age-related differences influence GLP-1 RA tolerability, although direct cross-trials comparisons are confounded: the older populations in Table 1 (SELECT, SOUL, FLOW, and the cardiovascular outcome trials; mean ages 62-67 years) received lower doses and, in several cases, had restricted safety-event capture, whereas the younger populations in obesity trials received the highest doses.^{14, 105 - 106} Within this limitation, GI-related discontinuation in the older CKD population of FLOW (4.5% vs 1.1%) was comparable to that in younger diabetes cohorts, arguing against a marked age-driven intolerance signal.^{14, 57, 97} Older patients may face greater constipation, dehydration, electrolyte disturbance, polypharmacy risks, and higher discontinuation, supporting lower starting doses and slower titration. Younger adults generally tolerate therapy well, while pediatric and adolescent use is increasing, with limited evidence regarding GIAEs in this group.^{10, 15, 55}

4.4 Sex-Related Differences

Female patients experience higher rates of GLP-1 RA-associated GIAEs, especially nausea, vomiting, abdominal pain, and constipation, likely due to sex hormone effects on motility, slower gastric emptying, visceral sensitivity, symptom reporting, and pharmacokinetic differences.^{93, 107} Sex-based dose adjustment is not recommended, but slower titration and symptom management are important. Sex composition also confounds cross-trial comparisons in Table 1: the obesity trials enrolled predominantly women (74-78% in the STEP program), whereas SELECT (72% male) and the cardiovascular outcome trials enrolled predominantly men. Part of the apparent indication-related gradient in GIAEs therefore reflects differences in population sex distribution, in addition to differences in GLP-1 RA dose.^{65, 71, 80, 106}

4.5 Other Comorbidities

Comorbidities and polypharmacy substantially affect GLP-1 RA tolerability. CKD generally does not require dose adjustment, and the FLOW trial provides direct reassurance: in patients with T2DM and CKD (mean eGFR 47 mL/min/1.73 m²), gastrointestinal related drug discontinuation was 4.5% versus 1.1% with placebo, and

overall discontinuation due to adverse events was only marginally higher than placebo (13.2% vs 11.9%) over a median 3.4 years (Table 1). The principal concern is vulnerability to dehydration, acute kidney injury, and electrolyte disturbance when vomiting or diarrhea does occur, warranting a lower threshold for laboratory reassessment and temporary dose interruption in this population.¹⁴ In patients with established cardiovascular disease, the outcome of trials (SELECT, SOUL, SURPASS-CVOT, HARMONY, REWIND) demonstrate cardiovascular benefit that generally outweighs GI concerns; in SELECT, despite GI events driving discontinuation in 10% of semaglutide-treated patients versus 2% with placebo, serious adverse events were less frequent with semaglutide than placebo.^{88, 94, 105 - 106} Concomitant cardiovascular medications may nonetheless contribute to GI symptoms. Hepatic impairment requires caution in advanced disease. Metformin, opioids, anticholinergics, and other GI-active drugs can amplify adverse effects, supporting medication review and individualized monitoring during therapy.

5. Management of Gastrointestinal Adverse Events

5.1 Preventive Strategies

Patient selection, risk assessment, and screening for pre-existing gastrointestinal disorders are essential to identify patients at increased risk of GIAEs and to guide individualized treatment and monitoring strategies. The baseline assessment should include a history of gastroparesis, chronic nausea, severe GERD, IBS, IBD, prior bowel obstruction or gastrointestinal surgery, and the use of opioids or other medications that affect GI motility.^{45, 108} In patients with suspected gastroparesis, a GES may be considered before initiating therapy.¹⁰⁹

Pre-treatment counseling and expectation setting are critical for improving treatment adherence and reducing premature discontinuation. Patients should be informed that GI symptoms, particularly nausea, are typically mild, transient, and most pronounced during the first month of therapy. They should also receive guidance on dose escalation and dietary modifications that may help minimize symptom severity.^{108, 110}

Gradual dose titration remains the most effective strategy for preventing GIAEs. Therapy should be initiated at the lowest recommended dose, such as semaglutide 0.25 mg weekly or liraglutide 0.6 mg daily, followed by gradual dose escalation. In patients who experience poor tolerability, extending the duration of each titration step may further reduce symptom burden, whereas rapid dose escalation increases the risk of GIAEs and treatment discontinuation.

5.2 Non-Pharmacological Interventions

Dietary modifications are the cornerstone of non-pharmacological management and can effectively reduce nausea, early satiety, abdominal discomfort, and bowel symptoms. Patients should be encouraged to consume small, frequent, low-fat meals, eat slowly, avoid foods that trigger symptoms, maintain adequate hydration, gradually increase dietary fiber to manage constipation, and consider temporary fiber reduction or a low-FOD-MAP diet if diarrhea predominates.¹¹¹

Adjusting meal timing and injection schedules may also improve tolerability, particularly by administering short-acting GLP-1 RA 30-60 minutes before meals or switching long-acting agents to bedtime in patients with significant nausea.^{111, 112}

Adequate hydration is especially important for individuals with vomiting or diarrhea and can be maintained through frequent small sips of fluids, clear liquids during severe nausea, oral rehydration solutions when needed. Excessive caffeine and alcohol intake should also be limited.^{111, 113}

Lifestyle measures further complement symptom management and include walking after meals, avoiding recumbency immediately after eating, elevating the head of the bed in patients with GERD, wearing loose-fitting clothing, practicing stress-reduction techniques, and maintaining a symptom diary to identify potential triggers.¹¹¹

5.3 Pharmacological Therapy

GIAEs are the most common cause of GLP-1 RA intolerance, affecting 28%-91% of patients. In the absence of

indications for treatment discontinuation, symptoms are best managed through gradual dose titration and dietary and lifestyle modification. Targeted pharmacological therapy should be considered when non-pharmacological interventions are insufficient to control symptoms.^{45, 97, 112} Pharmacotherapy is reserved for patients without an indication for discontinuation, in whom alternative etiologies have been excluded and non-pharmacological measures have failed. For nausea and vomiting, ondansetron (4-8 mg orally two to three times daily) is preferred; headache, constipation, and QT prolongation are the principal concerns. Metoclopramide (5-10 mg orally before meals and at bedtime) should be reserved for objectively DGE and limited to 12 weeks given the risk of tardive dyskinesia. Prochlorperazine is an alternative, with sedation and extrapyramidal effects. Diarrhea is treated with loperamide (2-4 mg after each loose stool, maximum 16 mg/day) and, when bile acid malabsorption is suspected, with sequestrants, administered at least 4 hours apart from oral semaglutide.^{45, 95, 109, 112} Constipation responds to soluble fiber, polyethylene glycol 17 g daily, or magnesium salts (should be avoided in CKD). Stimulant laxatives and secretagogues are reserved for refractory cases. No pharmacotherapy is established for abdominal pain.^{45, 95, 108, 114}

5.4 When to Stop GLP-1 RA Therapy and Refer to Gastroenterology or a Motility Specialist

GLP-1 RA should be discontinued in patients with severe or persistent gastrointestinal symptoms, suspected pancreatitis, significant gallbladder disease, or DGE that increases aspiration risk, especially in the perioperative setting (Table 2).^{95, 110, 114 - 115}

Table 2. Serious Gastrointestinal Adverse Events During GLP-1 RA Therapy. Recommended Action

Event	Recommended Action
Acute pancreatitis*	Discontinue; rechallenge not recommended
Confirmed gastroparesis (compatible symptoms + objectively DGE + obstruction excluded)	Discontinue; reassess motility after washout, as reversibility is incompletely defined
Bowel obstruction or ileus	Discontinue; surgical evaluation as indicated
Nausea/recurrent vomiting with volume depletion, acute kidney injury, or need for nutritional support	Interrupt; resume at lower dose only if symptoms fully resolve and no alternative cause is found
Severe constipation with fecal impaction	Interrupt; disimpaction and defecatory-disorder workup before considering resumption
Severe diarrhea with dehydration or electrolyte disturbance	Interrupt; exclude alternative causes before considering resumption
Acute cholecystitis or symptomatic cholelithiasis	Interrupt and treat biliary disease; resumption individualized
Intractable GI symptoms despite dose reduction and symptom-directed therapy	Discontinue; consider alternative agent or class

*An association between GLP-1 RA and pancreatitis remains debated; discontinuation is nonetheless standard practice pending evaluation.

Referral to a gastroenterologist or motility specialist should be considered in patients with suspected gastroparesis, particularly when nausea, vomiting, early satiety, or postprandial fullness persist despite discontinuation of GLP-1 RA therapy, when symptoms lead to significant nutritional compromise, or when food retention is identified on endoscopy.^{110, 115} Referral is also indicated for refractory GI symptoms that fail to improve despite dietary modification, slower dose titration, pharmacological therapy, or temporary drug discontinuation. Patients with medically refractory gastroparesis, defined by persistent symptoms and objectively documented DGE despite optimized antiemetic and prokinetic treatment, should be managed at specialized centers for multidisciplinary care.^{109 - 110, 114 - 115}

If food retention has progressed to a bezoar, endoscopic fragmentation with or without dissolution therapy remains first-line treatment. Intravenous erythromycin (3 mg/kg or 250 mg) or azithromycin (250 mg), both motilin receptor agonists, may be used adjunctively to stimulate antral contractility and promote clearance. Supporting data are limited to case reports and small series. QT prolongation warrants attention, and tachyphylaxis limits repeated administration.¹⁰⁹

Finally, patients requiring specialized motility testing, including GES, antroduodenal manometry, wireless motility capsule, or whole-gut transit studies, should be referred to tertiary motility centers.

6. Future Directions and Research Gaps

Expert consensus converges on three axes that define the next phase of GLP-1 RA development: expansion into non-glycemic, non-weight indications; higher-potency multi-agonist molecules (dual GIP/GLP-1, GLP-1–glucagon, GLP-1–amylin, triple GIP/GLP-1–glucagon); and oral small-molecule formulations to improve access and convenience. All three increase either the number of patients exposed or the intensity of receptor activation, with direct implications for gastrointestinal tolerability.^{32, 97, 116}

Formulations and receptor engineering. Oral semaglutide produces GIAEs rates comparable to injectable formulations, suggesting that systemic receptor activation, rather than route of administration, drives symptoms. Modified-release, ultra-long-acting, and targeted-delivery systems remain plausible strategies, but none has yet reduced GIAEs. Multi-agonist molecules may compound GE through additive effects on gastric emptying and visceral sensation; however, dedicated motility endpoints are largely absent from these programs.^{32 - 33}

Expanding indications. Weight-independent ben-

efits are documented in SELECT (cardiovascular), ESSENCE (liver), and STRIDE (peripheral artery disease), raising the question of whether optimal doses for these outcomes differ from those established for T2DM and obesity, a difference that could substantially alter the GIAEs profile. Results in neurodegeneration are mixed: EVOKE showed no effect on progression despite favorable observational signals, while trials in Parkinson disease yielded inconsistent results.^{13, 106, 117 - 118} In alcohol use disorder, Swedish registry data involving more than 227,000 individuals showed lower hospitalization with semaglutide (HR 0.64) and liraglutide (HR 0.72). More than 12 trials are currently ongoing.¹¹⁹

Adherence as the limiting factor. Discontinuation reaches 46.5% within 12 months in patients with T2DM and 64.8% in those without. Since GI intolerance is among the most cited reasons for therapy discontinuation, mitigating these symptoms may contribute as much to real-world outcomes as further gains in therapeutic potency.^{120 - 121}

Predictive biomarkers. Identifying patients at risk of GI intolerance before treatment initiation would allow individualized titration and prophylaxis. Candidate predictors include *GLP1 receptor* variants, baseline gastric emptying, microbiome signatures, and machine-learning-based pharmacogenomic models, all of which require prospective validation with standardized motility endpoints.^{32, 121}

7. Conclusion

Gastrointestinal adverse events are the dominant tolerability limitation of GLP-1 receptor agonist therapy and one of the leading drug-related reasons for treatment discontinuation. They arise from a dual peripheral-central mechanism: peripheral GLP-1 receptor activation delays gastric and small intestinal transit, while receptor activation at the area postrema and NTS drives nausea and emesis. There have been no RCT to compare use of antiemetics with prokinetics for nausea and emesis. The fact that there are no safe prokinetics is probably a pivotal reason why these GIAEs are managed predominantly by antiemetics.

Across clinical trials, nausea, vomiting, diarrhea, constipation, and abdominal pain follow a consistent dose- and indication-dependent gradient, with the greatest burden observed in higher-dose regimens for obesity and MASH and with multi-agonist molecules. Most symptoms are mild, emerge during dose escalation, and attenuate with continued exposure. However, symptoms persist in a clinically important minority of patients, and a smaller subset develops symptomatic gastroparesis.

Management therefore rests on anticipation rather than rescue: baseline screening for pre-existing motility and functional gastrointestinal disorders, explicit pre-treatment counseling, initiation at the lowest effective dose with gradual titration, and dietary and lifestyle measures before pharmacotherapy. Clinicians should also recognize the limited set of presentations -suspected pancreatitis, significant gallbladder disease, refractory symptoms, nutritional compromise, and periprocedural aspiration risk- that warrant discontinuation or subspecialty referral.

As this class expands into non-glycemic indications and higher-potency multi-agonists enter routine practice, both the number of exposed patients and the intensity of receptor activation will increase. The most pressing needs are prospective trials that incorporate standardized and validated motility measurements and endpoints, validated predictive biomarkers of gastrointestinal intolerance, and evidence-based management algorithms to replace the expert consensus on which current recommendations largely depend.

Intellectual property. *The intellectual property rights to the original content of this manuscript, including the text, tables, figures, and original figure designs, belong to the authors of this review. Any reproduction, adaptation, distribution, or reuse of these materials should be subject to appropriate authorization and acknowledgment of the authors, in accordance with applicable copyright and publication policies.*

Funding. *The authors declare that there were no external sources of funding.*

Conflict of interest. *Madhusudan Grover has received research grants from Takeda and Alfasigma pharmaceuticals. He advises Alfasigma pharmaceuticals with honoraria paid to his employer. Michael Camilleri serves as an adviser to Lilly with honoraria paid to his employer.*

Copyright



© 2026 Acta Gastroenterológica latinoamericana. This is an open-access article released under the terms of the Creative Commons Attribution (CC BY-NC-SA 4.0) license, which allows non-commercial use, distribution, and reproduction, provided the original author and source are acknowledged.

Cite this article as: Zúñiga Cisneros J, Camilleri M and Grover M. Glucagon-Like Peptide-1 Receptor Agonist and Gastrointestinal Adverse Effects: A Comprehensive Review. *Acta Gastroenterol Latinoam*. 2026;56(3):269-288. <https://doi.org/10.52787/agl.v56i3.690>

References

1. Ghusn W, Hurtado MD. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. *Obesity Pillars*. 2024;12. DOI:10.1016/j.obpill.2024.100127
2. Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. *Signal Transduct Target Ther*. 2024;9(1). DOI:10.1038/S41392-024-01931-Z
3. NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE - The Lancet. Accessed June 24, 2026. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(64\)90011-X/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(64)90011-X/fulltext)
4. Aaboe K, Krarup T, Madsbad S, Holst JJ. GLP-1: Physiological effects and potential therapeutic applications. *Diabetes Obes Metab*. 2008;10(11):994-1003. DOI:10.1111/J.1463-1326.2008.00853.X
5. Andrews CN, Bharucha AE, Camilleri M, et al. Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans. *Neurogastroenterol Motil*. 2007;19(9):716-723. DOI:10.1111/j.1365-2982.2007.00923.x
6. Jalleh RJ, Marathe CS, Rayner CK, et al. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. *Endocrinology*. 2024;166(1). DOI:10.1210/endo/bqae155
7. Wongjarupong N, Al-Hameed M, Suchartikitwong S, Assavapongpaiboon B, Salehian B. Glucagon-Like Peptide-1 Receptor Agonist Effects on Gastric Motility: A Systematic Review. In: 2020.
8. Filippatos TD, Panagiotopoulou T V, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. *Rev Diabet Stud*. 2014;11(3-4):202-230. DOI:10.1900/rds.2014.11.202
9. Smits MM, Van Raalte DH. Safety of Semaglutide. *Front Endocrinol (Lausanne)*. 2021;Volume 12-2021. DOI:10.3389/fendo.2021.645563
10. Xie X, Yang S, Deng S, Liu Y, Xu Z, He B. Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis. *Front Pharmacol*. 2025;Volume 16-2025. DOI:10.3389/fphar.2025.1613610
11. Xu D, Nair A, Sigston C, et al. Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. *Cardiovasc Ther*. 2022;2022:6820377. DOI:10.1155/2022/6820377
12. Klein KR, Clemmensen KKB, Fong E, Olsen S, Abrahamsen T, Lingvay I. Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6. *Diabetes Care*. 2024;47(2):280-284. DOI:10.2337/dc23-1791
13. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. *New England Journal of Medicine*. 2025;392(21):2089-2099. DOI:10.1056/NEJMoa2413258

14. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 2024;391(2):109-121. DOI:10.1056/NEJMoa2403347
15. Yilmaz N, Bastemir M. Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations. *Diabetes Metab Syndr Obes*. 2026;19:584175. DOI:10.2147/dmso.S584175
16. Li P, Varghese JS, Shah MK, et al. Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity. *JAMA Netw Open*. 2025;8(10):e2540890-e2540890. DOI:10.1001/JAMANETWORKOPEN.2025.40890
17. Berning P, Adhikari R, Schroer AE, et al. Longitudinal Analysis of Obesity Drug Use and Public Awareness. *JAMA Netw Open*. 2025;8(1):e2457232-e2457232. DOI:10.1001/JAMANETWORKOPEN.2024.57232
18. Aldhaleei WA, Abegaz TM, Bhagavathula AS. Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort. *Pharmaceuticals (Basel)*. 2024;17(2). DOI:10.3390/ph17020199
19. Jalleh RJ, Talley NJ, Horowitz M, Nauck MA. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. *J Clin Invest*. 2026;136.
20. Fadini GP, Morieri ML, Boscaro C, Bonora BM, Cignarella A. Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability. *Diabetes Obes Metab*. 2026;28(7):6405-6412. DOI:10.1111/DOM.70840
21. Ahn CH, Oh TJ, Min SH, Cho YM. Incretin and Pancreatic β -Cell Function in Patients with Type 2 Diabetes. *Endocrinol Metab (Seoul)*. 2023;38(1):1-9. DOI:10.3803/EnM.2023.103
22. Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. *Exp Diabetes Res*. 2011;2011:279530. DOI:10.1155/2011/279530
23. Thazhath SS, Marathe CS, Wu T, et al. The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial. *Diabetes*. 2016;65(1):269-275. DOI:10.2337/db15-0893
24. Kawatani M, Yamada Y, Kawatani M. Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons. *Peptides (NY)*. 2018;107:68-74. DOI:10.1016/j.peptides.2018.07.010
25. Turcano P, Savica R, Benarroch E. What Is the Role of Glucagon-Like Peptide 1 Signaling in the Nervous System and Its Potential Neuroprotective Effects? *Neurology*. 2024;103(4). DOI:10.1212/WNL.0000000000209781
26. Zhang T, Perkins MH, Chang H, Han W, de Araujo IE. An inter-organ neural circuit for appetite suppression. *Cell*. 2022;185(14):2478. DOI:10.1016/j.cell.2022.05.007
27. Halim MA, Degerblad M, Sundbom M, et al. Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans. *J Clin Endocrinol Metab*. 2018;103(2):575-585. DOI:10.1210/JC.2017-02006
28. Lu Z, Yeung CK, Lin G, Yew DTW, Andrews PLR, Rudd JA. Centrally located GLP-1 receptors modulate gastric slow waves and cardiovascular function in ferrets consistent with the induction of nausea. *Neuropeptides*. 2017;65:28-36. DOI:10.1016/j.npep.2017.04.006
29. Huang KP, Acosta AA, Ghidewon MY, et al. Dissociable hindbrain GLP1R circuits for satiety and aversion. *Nature*. 2024;632(8025):585-593. DOI:10.1038/S41586-024-07685-6
30. Borner T, Geisler CE, Fortin SM, et al. GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models. *Diabetes*. 2021;70(11):2545-2553. DOI:10.2337/DB21-0459
31. Ding H, Wang M, Zhang J, et al. Exendin-4 induced retching-like behavior mediated by postsynaptic effect via AMPA receptors in the area postrema of mice. *Am J Physiol Endocrinol Metab*. 2025;329(2):E254-E265. DOI:10.1152/AJPENDO.00174.2025
32. Rosen CJ, Ingelfinger JR. GLP-1 Receptor Agonists. *N Engl J Med*. 2026;394(13):1313-1324. DOI:10.1056/NEJMRA2500106;WGROU:STRING:MMS
33. Bellavance D, Chua S, Mashimo H. Gastrointestinal Motility Effects of GLP-1 Receptor Agonists. *Curr Gastroenterol Rep*. 2025;27(1):49. DOI:10.1007/s11894-025-00995-3
34. Camilleri M, Carlson P, Dilmaghani S. Prevalence and Variations in Gastric Emptying Delay in Response to GLP-1 Receptor Agonist, Liraglutide. *Obesity (Silver Spring)*. 2023;32(2):232. DOI:10.1002/OBY.23941
35. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes. *J Clin Endocrinol Metab*. 2003;88(6):2719-2725. DOI:10.1210/jc.2003-030049
36. Gentilella R, Pechtner V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? *Diabetes Metab Res Rev*. 2019;35(1):e3070. DOI:10.1002/DMRR.3070;JOURNAL:JOURNAL:10990895;REQUESTEDJOURNAL:JOURNAL:15207560;WGROU:STRING:PUBLICATION
37. Chen A, Zhao K, Ceban F, et al. Glucagon-like peptide-1 receptor agonists and gastric emptying time: a systematic review and meta-analysis of prospective studies. *Can J Anaesth*. 2026;73(4):345-356. DOI:10.1007/S12630-026-03114-6
38. Quast DR, Schenker N, Menge BA, Nauck MA, Kapitza C, Meier JJ. Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes. *Diabetes Care*. 2020;43(9):2137-2145. DOI:10.2337/DC20-0720
39. Maselli DB, Camilleri M. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. *Adv Exp Med Biol*. 2021;1307:171-192. DOI:10.1007/5584_2020_496
40. Lupianez-Merly C, Dilmaghani S, Vosoughi K, Camilleri M. Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks. *Aliment Pharmacol Ther*. 2024;59(4):475-491. DOI:10.1111/APT.17856;REQUESTEDJOURNAL:JOURNAL:13652036;ISSUE:ISSUE:DOI
41. Maselli D, Atieh J, Clark MM, et al. Effects of Liraglutide on Gastrointestinal Functions and Weight in Obesity: A Randomized Clinical and Pharmacogenomic Trial. *Obesity (Silver Spring)*. 2022;30(8):1608. DOI:10.1002/OBY.23481
42. Jalleh RJ, Plummer MP, Marathe CS, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. *J Clin Endocrinol Metab*. 2024;110(1):1-15. DOI:10.1210/clinem/dgae719

43. Jones KL, Huynh LQ, Hatzinikolas S, et al. Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations. *Diabetes Obes Metab.* 2020;22(5):788-797. DOI:10.1111/DOM.13956;WEBSITE:WEB-SITE:DOM-PUBS;WGROU:STRING:PUBLICATION
44. Meier JJ, Menge BA, Schenker N, et al. Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes. *Diabetes Obes Metab.* 2020;22(4):599-611. DOI:10.1111/DOM.13935;WEBSITE:WEBSITE:DOM-PUBS;WGROU:STRING:PUBLICATION
45. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. *J Clin Med.* 2022;12(1). DOI:10.3390/jcm12010145
46. Baumer-Harrison C, Aldaghma D, White AD, et al. GLP-1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models. *Diabetes Obes Metab.* 2026;28(3):2317-2328. DOI:10.1111/DOM.70427; JOURNAL:JOURNAL:14631326;WESITE:WEBSITE:DOM-PUBS;WGROU:STRING:PUBLICATION
47. Herfarth H, Long MD, Hansen JJ, et al. Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study. *Am J Gastroenterol.* 2024;119(9):1935-1938. DOI:10.14309/AJG.0000000000002801
48. May AT, Crowe MS, Blakeney BA, et al. Identification of expression and function of the glucagon-like peptide-1 receptor in colonic smooth muscle. *Peptides (NY).* 2019;112:48-55. DOI:10.1016/j.peptides.2018.11.007
49. Wegeberg AML, Hansen CS, Farmer AD, et al. Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial. *United European Gastroenterol J.* 2020;8(6):695-704. DOI:10.1177/2050640620925968
50. Cymbal M, Naseem Z, Hoxha D, Garg S. Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series. *ACG Case Rep J.* 2025;12(8):e01789. DOI:10.14309/crj.0000000000001789
51. Atieh J, Camilleri M, Halawi H. Mo1813 GLP-1 Receptor Agonists Are Associated With Delayed Colonic Transit: A Propensity Score-Weighted Retrospective Cohort Study. *Gastroenterology.* 2026;170(6):S-2078. DOI:10.1016/s0016-5085(26)04946-2
52. Greiner TU, Koh A, Peris E, et al. GLP-1R signaling modulates colonic energy metabolism, goblet cell number and survival in the absence of gut microbiota. *Mol Metab.* 2024;83. DOI:10.1016/j.molmet.2024.101924
53. Sun H, Shu J, Tang J, et al. GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells. *Immunology.* 2024;172(3):451-468. DOI:10.1111/IMM.13784;SUBPAGE:STRING:FULL
54. Horowitz M, Aroda VR, Han J, Hardy E, Rayner CK. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences. *Diabetes Obes Metab.* 2017;19(5):672-681. DOI:10.1111/DOM.12872; CTYPE:STRING:JOURNAL
55. Chiang CH, Jaroenlapnopparat A, Colak SC, et al. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. *Gastroenterology.* 2025; 169(6):1268-1281. DOI:10.1053/j.gastro.2025.06.003
56. Kang YM, Punov V, Lim S, Nauck MA. Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials. *Diabetes Obes Metab.* 2025;27(7):3736-3746. DOI:10.1111/DOM.16398
57. Zhang Z, Zhang Q, Tan Y, et al. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. *Front Endocrinol (Lausanne).* 2023;Volume 14-2023. DOI:10.3389/fendo.2023.1149328
58. Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine.* 2017;377(13):1228-1239. DOI:10.1056/NEJMoa1612917
59. Halawi H, Khemani D, Eckert D, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. *Lancet Gastroenterol Hepatol.* 2017; 2(12):890-899. DOI:10.1016/S2468-1253(17)30285-6
60. Zinman B, Aroda VR, Buse JB, et al. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. *Diabetes Care.* 2019;42(12):2262-2271. DOI:10.2337/dc19-0898
61. Joy B, Ramsamooj A, Ibrahim S, Wen J, Hsu N, Frezza E. Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials. *Endocrine.* 2026;91(1):23. DOI:10.1007/s12020-025-04494-3
62. Jenkins W, Nassar M, Ghanim H. Gastroparesis Incidence Post-Initiation of Semaglutide Versus Sitagliptin in Type 2 Diabetes: A Retrospective TriNetX Database Analysis. *Endocrine Practice.* 2024;30(5):S35-S36. DOI:10.1016/j.eprac.2024.03.189
63. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. *The Lancet.* 2021;398(10296):262-276. DOI:10.1016/S0140-6736(21)00536-5
64. Sun F, Chai S, Yu K, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. *Diabetes Technol Ther.* 2015;17(1):35-42. DOI:10.1089/dia.2014.0188
65. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. *JAMA.* 2021;325(14):1414-1425. DOI:10.1001/jama.2021.3224
66. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. *Lancet Diabetes Endocrinol.* 2017;5(5):355-366. DOI:10.1016/S2213-8587(17)30085-2
67. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. *Diabetes Care.* 2019;42(9):1724-1732. DOI:10.2337/dc19-0749

68. Bajaj HS, Welch M, Shah P, *et al.* Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. *The Lancet*. DOI:10.1016/S0140-6736(26)00967-0
69. Bhattarai HB, Paudel BS, Parajuli SR, *et al.* Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis. *Medicine*. 2025;104(52):e46671. DOI:10.1097/md.00000000000046671
70. Dahl D, Onishi Y, Norwood P, *et al.* Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. *JAMA*. 2022;327(6):534-545. DOI:10.1001/jama.2022.0078
71. Davies M, Færch L, Jeppesen OK, *et al.* Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *The Lancet*. 2021;397(10278):971-984. DOI:10.1016/S0140-6736(21)00213-0
72. Del Prato S, Kahn SE, Pavo I, *et al.* Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *The Lancet*. 2021;398(10313):1811-1824. DOI:10.1016/S0140-6736(21)02188-7
73. Marso SP, Bain SC, Consoli A, *et al.* Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 2016;375(19):1834-1844. DOI:10.1056/NEJMoa1607141
74. Wilding JPH, Batterham RL, Calanna S, *et al.* Once-Weekly Semaglutide in Adults with Overweight or Obesity. *New England Journal of Medicine*. 2021;384(11):989-1002. DOI:10.1056/NEJMoa2032183
75. Jastreboff AM, Kaplan LM, Frías JP, *et al.* Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. *New England Journal of Medicine*. 2023;389(6):514-526. DOI:10.1056/NEJMoa2301972
76. Loomba R, Hartman ML, Lawitz EJ, *et al.* Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. *New England Journal of Medicine*. 2024;391(4):299-310. DOI:10.1056/NEJMoa2401943
77. Wadden TA, Chao AM, Machineni S, *et al.* Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. *Nat Med*. 2023;29(11):2909-2918. DOI:10.1038/s41591-023-02597-w
78. Aronne LJ, Sattar N, Horn DB, *et al.* Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. *JAMA*. 2024;331(1):38-48. DOI:10.1001/jama.2023.24945
79. Jastreboff AM, Aronne LJ, Ahmad NN, *et al.* Tirzepatide Once Weekly for the Treatment of Obesity. *New England Journal of Medicine*. 2022;387(3):205-216. DOI:10.1056/NEJMoa2206038
80. Wadden TA, Bailey TS, Billings LK, *et al.* Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. *JAMA*. 2021;325(14):1403-1413. DOI:10.1001/jama.2021.1831
81. Sorli C, Harashima S ichi, Tsoukas GM, *et al.* Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. *Lancet Diabetes Endocrinol*. 2017;5(4):251-260. DOI:10.1016/S2213-8587(17)30013-X
82. Rosenstock J, Wysham C, Frías JP, *et al.* Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. *The Lancet*. 2021;398(10295):143-155. DOI:10.1016/S0140-6736(21)01324-6
83. Rosenstock J, Allison D, Birkenfeld AL, *et al.* Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. *JAMA*. 2019;321(15):1466-1480. DOI:10.1001/jama.2019.2942
84. Pratley R, Amod A, Hoff ST, *et al.* Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. *The Lancet*. 2019;394(10192):39-50. DOI:10.1016/S0140-6736(19)31271-1
85. Pi-Sunyer X, Astrup A, Fujioka K, *et al.* A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. *New England Journal of Medicine*. 2015;373(1):11-22. DOI:10.1056/NEJMoa1411892
86. Mosenzon O, Blicher TM, Rosenlund S, *et al.* Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. *Lancet Diabetes Endocrinol*. 2019;7(7):515-527. DOI:10.1016/S2213-8587(19)30192-5
87. Pieber TR, Bode B, Mertens A, *et al.* Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. *Lancet Diabetes Endocrinol*. 2019;7(7):528-539. DOI:10.1016/S2213-8587(19)30194-9
88. Nicholls SJ, Pavo I, Bhatt DL, *et al.* Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. *New England Journal of Medicine*. 2025;393(24):2409-2420. DOI:10.1056/NEJMoa2505928
89. Newsome PN, Buchholtz K, Cusi K, *et al.* A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. *New England Journal of Medicine*. 2021;384(12):1113-1124. DOI:10.1056/NEJMoa2028395
90. Garvey WT, Frias JP, Jastreboff AM, *et al.* Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *The Lancet*. 2023;402(10402):613-626. DOI:10.1016/S0140-6736(23)01200-X
91. Frías JP, Davies MJ, Rosenstock J, *et al.* Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 2021;385(6):503-515. DOI:10.1056/NEJMoa2107519
92. Armstrong MJ, Gaunt P, Aithal GP, *et al.* Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet*. 2016;387(10019):679-690. DOI:10.1016/S0140-6736(15)00803-x

93. Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. *Front Endocrinol (Lausanne)*. 2022;13. DOI:10.3389/FENDO.2022.1043789
94. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*. 2019;394(10193):121-130. DOI:10.1016/S0140-6736(19)31149-3
95. Staller K, Neshatian L, Lembo A, Bharucha AE. AGA Clinical Practice Update on Evaluation and Management of Refractory Constipation: Expert Review. *Clinical Gastroenterology and Hepatology*. 2026;24(2):296-305. DOI:10.1016/j.cgh.2025.09.031
96. Guo L, Zhang B, Hou J, Zhou Z. Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials. *Diabetes Ther*. 2020;11(8):1821-1833. DOI:10.1007/s13300-020-00869-z
97. Abdelrahman RM, Musa TH, Arbab IA, et al. Adverse effects of GLP-1 receptor agonists: Clinical Implications, regulatory perspectives, and future directions. *Obes Med*. 2026;61:100699. <https://doi.org/10.1016/j.obmed.2026.100699>
98. Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan M. The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials. *Diabetes Metab Syndr Obes*. 2023;16:575-595. DOI:10.2147/dmso.S387116
99. He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. *JAMA Intern Med*. 2022;182(5):513-519. DOI:10.1001/JAMAINTERNMED.2022.0338
100. Anderson KL, Feuerstein JD, University AJCET at M. GLP-1RAs increase risk for cholelithiasis and GERD but not other GI or biliary adverse events vs placebo. 2026;179(1). DOI:10.7326/ANNALS-25-05161-JC
101. Tartaglia E, Bucci T, Rossi M, et al. Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network. *Cardiovasc Diabetol*. 2025;24(1). DOI:10.1186/S12933-025-02986-0
102. Ramírez-Mejía MM, Ponciano-Rodríguez G, Eslam M, Méndez-Sánchez N. GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications. *Ther Adv Endocrinol Metab*. 2025;16:20420188251406456. DOI:10.1177/20420188251406456
103. Bharucha AE, Kudva YC, Prichard DO. Diabetic Gastroparesis. *Endocr Rev*. 2019;40(5):1318-1352. DOI:10.1210/ER.2018-00161
104. Bharucha AE, Kudva Y, Basu A, et al. Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes. *Clinical Gastroenterology and Hepatology*. 2015;13(3):466-476.e1. DOI:10.1016/j.cgh.2014.06.034
105. McGuire DK, Marx N, Mulvagh SL, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. *New England Journal of Medicine*. 2025;392(20):2001-2012. DOI:10.1056/NEJMoa2501006
106. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *New England Journal of Medicine*. 2023;389(24):2221-2232. DOI:10.1056/NEJMoa2307563
107. Gao R, Li Y, Li A, Zhou P, Zong H, Li Y. Risk factor screening and prediction modeling of gastrointestinal adverse reactions caused by GLP-1RAs. *Front Endocrinol (Lausanne)*. 2024;15:1502050. DOI:10.3389/FENDO.2024.1502050/BIBTEX
108. Saha B, Kamalumpundi V, Codipilly DC. GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians. *Mayo Clin Proc*. 2025;100(12):2228-2236. DOI:10.1016/j.mayocp.2025.09.017
109. Staller K, Parkman HP, Greer KB, et al. AGA Clinical Practice Guideline on Management of Gastroparesis. *Gastroenterology*. 2025;169(5):828-861. DOI:10.1053/j.gastro.2025.08.004
110. Moiz A, Peters TM, Tsoukas MA, Yu OHY, Filion KB, Eisenberg MJ. Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making. *EClinical Medicine*. 2026;96. DOI:10.1016/J.ECLINM.2026.103991
111. Mehrtash F, Dushay J, Manson JAE. Integrating Diet and Physical Activity When Prescribing GLP-1s-Lifestyle Factors Remain Crucial. *JAMA Intern Med*. 2025;185(9):1151-1152. DOI:10.1001/JAMAINTERNMED.2025.1794
112. Kushner RF, Almandoz JP, Rubino DM. Managing Adverse Effects of Incretin-Based Medications for Obesity. *JAMA*. 2025;334(9):822-823. DOI:10.1001/JAMA.2025.11153
113. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. *Am J Clin Nutr*. 2025;122(1):344-367. DOI:10.1016/J.AJCNUT.2025.04.023
114. Moshiree B, Drossman D, Shaikat A. AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review. *Gastroenterology*. 2023;165(3):791-800.e3. DOI:10.1053/j.gastro.2023.04.039
115. Lacy BE, Tack J, Gyawali CP. AGA Clinical Practice Update on Management of Medically Refractory Gastroparesis: Expert Review. *Clinical Gastroenterology and Hepatology*. 2022;20(3):491-500. DOI:10.1016/j.cgh.2021.10.038
116. Sun F, Yu K, Yang Z, et al. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. *Exp Diabetes Res*. 2012;2012:230624. DOI:10.1155/2012/230624
117. Cummings JL, Atri A, Sano M, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evolve and evoke+): two phase 3, randomised, placebo-controlled trials. *The Lancet*. 2026;407(10544):2167-2179. DOI:10.1016/S0140-6736(26)00459-9
118. Bonaca MP, Catarig AM, Houliand K, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. *The Lancet*. 2025;405(10489):1580-1593. DOI:10.1016/S0140-6736(25)00509-4
119. Lähteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittenborfer-Rutz E, Taipale H. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. *JAMA Psychiatry*. 2025;82(1):94-98. DOI:10.1001/JAMAPSYCHIATRY.2024.3599

120. Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. *JAMA Netw Open*. 2025;8(1):e2457349-e2457349. DOI:10.1001/jamanetworkopen.2024.57349
121. Gonzalez-Rellan MJ, Drucker DJ. New Molecules and Indications for GLP-1 Medicines. *JAMA*. 2025;334(14):1231-1234. DOI:10.1001/JAMA.2025.14392
122. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. *The Lancet*. 2021;398(10300):583-598. DOI:10.1016/S0140-6736(21)01443-4
123. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *The Lancet*. 2018;392(10157):1519-1529. DOI:10.1016/S0140-6736(18)32261-X
124. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. *New England Journal of Medicine*. 2015;373(23):2247-2257. DOI:10.1056/NEJMoa1509225
125. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nature Medicine* 2022 28:10. 2022;28(10):2083-2091. DOI:10.1038/s41591-022-02026-4